Certis Oncology Solutions Fuels $42 Million Growth Engine to Personalize Cancer Care
AI and Advanced Testing Boost Certis Oncology:
Life science innovator Certis Oncology Solutions has secured $42 million in new funding, bringing its total capital to an impressive sum.
This undisclosed investor backing fuels the company’s mission to personalize cancer treatment through AI-powered drug development and advanced functional testing.
Oncology Intelligence™: Predicting the Right Path:
Certis’ flagship product, Oncology Intelligence™, leverages cutting-edge algorithms to generate highly predictive data on therapeutic response.
These insights, derived from sophisticated cancer models, empower doctors to tailor treatment plans to individual patients, maximizing effectiveness and minimizing side effects.
From Lab to Clinic: Personalized Precision:
Since 2016, Certis has pioneered personalized functional testing.
This approach goes beyond traditional biopsies, utilizing patient-derived tumor models and AI to assess how specific drugs might impact individual cancer cells.
This crucial information, validated in their CLIA-certified San Diego laboratory, guides clinicians in selecting the most promising treatment options.
Expanding the Impact:
With the new funding, Certis aims to scale its operations and development efforts.
This translates to more personalized cancer care reaching more patients worldwide, accelerating the journey towards precision oncology.
Leadership Strength:
Alongside the funding news, Certis announced the appointment of John R. Tozzi as Chairman of its Board of Directors.
Tozzi’s extensive experience in healthcare and technology adds vital expertise as Certis navigates its ambitious growth path.
Certis Oncology Solutions stands at the forefront of the fight against cancer, harnessing the power of AI and advanced testing to personalize treatment and improve patient outcomes.
With this latest funding and strengthened leadership, the company is poised to make a significant impact on the landscape of cancer care.